สรุปวิเคราะห์และรวบรวมผลงานวิจัยต่างๆ ที่มีผู้ส่งเข้าประกวดในปี 2554 เป็นคลังความรู้สำหรับผู้สนใจสามารถใช้ต่อยอดการทำงานด้านความรู้ และปฏิบัติการบนฐานความรู้ให้มีความคืบหน้าต่อไป :สถาบันวิจัยระบบสาธารณสุข
2. +:83#:D?L59!: R2R # beed 29D 3. +:83#:D?L59!: R2R# beed 33
8FCTJUF IUUQSSITSJPSUI 4. I 5. R2R 2554 1 2554 2,000 ISBN
978-974-299-165-4 .. . . .. .. .. . . . . . . . .. . . . . . . . .
.. . .. . . . . .. .. . . . .. . . . . . . 0 2903 8257-9 II 6.
Routine to Research (R2R) 2551 R2R (.) 300-400 R2R 4 2554 R2R R2R
R2R (link of research to policy and practice) (Routine to Research
to Policy: R2R2P) . 2554 . 2554 III 7. III 4 (2554)1 3 (2552-2554)3
R2R 1 9 R2R 2 12 R2R 3 15 R2R 4 18 4A 4B 21 1 25- ID28 : 28 - ID116
: 30 - ID182 32 - ID236 ;34 - ID278 36- ID314 38 - ID54 : 42 - ID90
.. 44 - ID163 46 - ID173 : 48 - ID185 50 - ID248 10 : 52 - ID354 54
IV 8. - ID4 58- ID12 60 - ID17 62 - ID39 . 64 - ID44 . 66- ID71 /
68 - ID79 70- ID98 skin traction 72- ID130 74 - ID135 76 - ID158 :
78 - ID186 Metabolic Syndrome 80 - ID188 82 - ID190 84 - ID193 :
86- ID202 slim up 88- ID219 90 - ID237 .. CUP -92- ID244 94- ID280
96 - ID292 98 - ID327 : 100- ID328 102V 9. - ID333 104 - ID340 106
- ID363 108 2 - ID6 114- ID43 116- ID48 118- ID112 120- ID159 Three
in one 122- ID201 124- ID206 CONDOM : Permanent catheter condom126-
ID233 128 - ID5 132 1 2549-2552 - ID15 134 - ID36 Modified Early
Warning Signs Score 136 - ID42 138 - ID57 140 - ID332 142 - ID346
144 - ID357 146 3 - ID108 152 - ID110 154 -131 - ID115
Dexamethasone 156 - ID118 158VI 10. - ID125 160-131- ID164 162 6 -
ID170 164- ID197 24 166 Missed injuries- ID218 168 - ID223 Knee
Exercise 170- ID269 172- ID356 Model Reload 174- ID34 : 178 - ID65
180- ID78 182 - ID134 184- ID143 186 : 5.5 - ID230 : 188- ID238
190- ID252 192 2- ID313 194- ID347 196- ID37 /200 /: 2553- ID93
Ceftriaxone 202 VII 11. - ID107 204 - ID113 Polyethylene glycol206
Sodium phosphate - ID119 Burirams model 208 - ID123 210 - ID127 212
Gas/Silcone oil - ID131 214 - ID187 216 - ID189 218 - ID211 Bonding
220 Elective - ID212 PJ 222 - ID225 224 - ID282 226 - ID291
Modified Lying Position 228 - ID312 230 - ID337 232 - ID355 234 4 /
- ID18 240- ID21 242- ID31 244- ID33 246- ID50 Internet248- ID121
MONITOR ALARM WATER PUMP250- ID140 Facebook: Adult . 252- ID157
254- ID183 : 256 eStock online Delivery VIII 12. - ID229 258 ()-
ID271 STEMI260- ID310 - LEAN 262- ID316 5 264- ID348 TACE266- ID366
Decha Program268 - ID8 272- ID82 274 - ID88 High kVp Technique 276-
ID152 278- ID349 elective 280 - ID45 284 - ID64 Step286- ID75 288
(FM-PRM/1-01)- ID85 290 - ID126 292 - ID129 : 294 - ID133 Water Jet
Pump296- ID154 298- ID165 300 - ID167 Active Supervision Model: 302
IX 13. - ID191 304 .. 2551-2553- ID249 306- ID250 308- ID296 310 -
ID298 312 CUP--- ID300 : 314- ID336 316 2009 (H1N1) - ID339 Lean
Laboratory 318- ID343 320 - ID371 ADR 322X 14. 4 (2554) .. 370 362
8 4, 3 1 4 1 2 (.) 3 (.) (.) ( ) . 4 2 4A 4B (KM) 2 KM 1 1 2554
1234A4B 1. ./..381 39 2. . 1 23 3. .38 51228 119 4. . 55 5. ./. 12
72 21 9 114 6. .538 7. 44 8. 4 293 238 9. . 142 18 10. .1111 11. 6
2 19 12. .11 13. 11 14. 2 2 10151 113 52 45362 R2R 25541 15. 2 . 51
119 1, 4A 4B . .. . . . . 10-15 15 2 2 1 2 3 4 AP Pr A P Pr AP PrAP
Pr 1. ./.. 24 7 13 2. . 2 2 3. . 32 13 88 2 2 8 46 4. . 0 5. ./. 1
1 6 3 9 5 2 5 32 6. . 11 7. 1 1 2 8. 2 6 6 8 3 126 9. .1 1 1 3 6
10. . 3 1 4 11. 2 2 12. . 0 13. 1 1 14. 067 26 8 8 0 12 10 1815 5
20 135 39 1640 40 A = Award (), P = Poster, Pr = Print .. 33%
(13/39), . 67% (2/3), . 39% (46/119), ./. 28% (32/114), . 68%
(26/38), . 75% (6/8), . 36% (4/11) (R2R) 4 20-22 25542 16. 3
(2552-2554) .. A. 1 2 3 4 2 3 4 3 4 1 ./. 678710121 39 2 . 14158
5117 16 3 ./. / .150 10311333 40 4 4A .. 4A 4224 5220 40 4B .//4B /
45 45 KM/ 521 11 6Back office 23 11 7R2R 64445 322362117135 2 3 4 2
2 . 3 7 4 4 B. 2552-4 445, 322 362 2 (.) 2 . . . R2R 25543 17. 1 2
2554 2 2552 50 2 2 3 495 43 32 175117129 35 49 7051 48 49
25625728089 65 82 445322362 ./.. ./. . . . 2553 2552 2554 3 3 2 3 4
./.. 53 3939 . 14 53 .141 89 119 . 16 25 ./. 132122 114 356257 280
4 4 2 3 4 (18 ) 17 1211 (19 ) 17 1515* (24 )15 1716 (14 ) 109 9 *
20 (R2R) 4 20-22 25544 18. 1 2 5 5 2 3 4 1 22 106 2 12 7 , 5 1 12
49 34 2 43 1821 1 6 9 12 2 , 57 10 1 14 1311 2 7 12 10 6 2 3 4./..
10 7 13 9 5 54 3 / .3. 4 2 13 / / 1 12 . 1. 15 10 16 13 9 1311 7 9
/ 8../. 33 37 1011 11 9 9 9 /8/.. 9 1 32 1 1 1 R2R 2554 5 19.
12-13-14 7 14 --- ( ) 10 13 --- ( ) 12 --- 15 16 ( 15) ( 16) 8 6 8
3 6 3 2552 1 R2R 7 . 8 . 2 3 4 2 3 41 1011251 6731 2228 -132
161083414 63 122 2438 104 1818 4058335 1111 136 1620246620 177613
77 3117 278 2915188 187269313139 6861 26 10 114 12 10 5832 50 1173
14 11 1420 28 12 311727 12 3728 21 13 583250 14 686126 15 382011 16
291111 17 1610 8 18 1122 (R2R) 4 20-22 25546 20. . . 8 2552 3 9, 1
10 2553 3 2554 10, 4 11 . 10 . 13 --- . 9 --- 4 . 14 2554 1 . 1 15
16 . . 2554 3 2554 . 4 11 2 . 4 (12 ) (10 ) (8 ) 1-2 . 11 2554 (11
) (10 ) (6 ) 1 (, , ) 3 2 9 . . . . . 2 . . . 7 2552 2554 2552 2553
. . . . . . . . 4 2552-3 2554 5 2553 2554 . 3 2553 2552 2554 .
12-13 . . 1 4 2553-2554 R2R 2554 7 21. 9 2 3 4 . .. 3 .1 . .. 7 . 9
. 2 . 1 . 3 . 2 . 2 . 1 . 1 .1 Children Friendly Hospital 1 . ..1 .
1 .3 . 1 .1 .4 . 1 .1 . 1 7 6 1 2 1 1 2 1 1 2 1 2 1 1 . 1 1 1 1 1 1
2 6 5 5 4 . 3 5 3 3 1 3 5 3 .2 . .2 1 / 13 12 13 7 2 10 6 18 6 1 4
6 42 1 1 1 .1 . 1 89 6582 (R2R) 4 20-22 25548 22. R2R 1 . 1. 1.1
2554 101 2554 2553 ( 87 ) 14 / ( 38 ) / ( 12) ( 6) 1.2 ( 48) ( 20)
/// ( 11) 2( 1) ( 20) ( 19) ( 6) 4 1 4847.5 2019.8 ///1110.9 6 5.9
/4 4.0 /2 2.0 3 3.0 7 6.9 101100 R2R 25549 23. 1.3 1.3.1 (research
design) 1.3.2 18 (PAR) 15 (Action research) 10 1.3.3 1) 2) 3) 4)
1.3.4 2. 5 ( 71) ( 2) ( 8 ) 2 1 34 36.6 2 32 34.4 3 14 15.1 4 11.1
5 12 12.9 93100 3. 3.1 3.2 (R2R) 4 20-22 2554 10 24. 3.3
(Work-based research training) R2R 2554 11 25. R2R 2 1. 1.1 R2R 51
35 R2R three in one R2R R2R 1.2 R2R 1 3 3 1 1 R2R 1. / 18 35.32.
35.93. 27 52.94. 35.951 100 50 permanent catheter (R2R) 4 20-22
2554 12 26. 2. 30 2 2 R2R 1 1325.5 2 2752.9 3 713.7 4 4 7.6 5 -
-511003. 3.1 3.2 R2R 3.3 R2R 255413 27. 3.4 R2R R2R 3.5 R2R R2R R2R
R2R R2R R2R R2R 1) 2) priority agenda R2R 3) R2R 4) / R2R R2R ( .
.) (R2R) 4 20-22 2554 14 28. R2R 3 .. 1. 1.1 R2R 2554 113 23 1-7 5
(10 ) (8 ) (6 ) (3 ) (2 ) (1 ) 1.2 descriptive study experimental
(Quasi,innovation) 37 action research 21 clinical trial/RCT 12 6
1.3 84 19 8 1 descriptive study 1.4 4 theme based monitor and
evaluation 26 management 23 service delivery 53 empowerment 32 ( 2
theme 113 ) theme management 23 10 1.5 disease based 1 1 disease
based Disease based 21 2 + 13 3 + 14 2 HT, CHD, CVD 9 1Psychiatry
9DM 8Chronic renal disease4Cancer 4 Emergency 9 1 Nursing care7 2
Others (Frequency5) 19 1 () 11612 HT = hypertension, CHD = coronary
heart disease, CVD = cardiovascular disease R2R 2554 15 29. 2. 5 2
R2R 1 63 55.8 2 46 40.7 3 1 0.9 4 3 2.7 5 0 0 113100 15 Model
reload () Mobile toilet 10 113 42 32 10 10 6 5 3 18 42 manuscript
40 20 20 6 ( 3 2 1 ) 6 6 ( ) poster 10 (R2R) 4 20-22 2554 16 30. 3.
3.1 73 CQI () R2R 3.2 3.3 (2 ) 1 47 2 () R2R 1. R2R 2. 3. R2R 2554
17 31. R2R 4 4A 4B . 1. 1.1 4A 52 4B 45 30 R2R R2R 1 1.2 R2R 1 1 18
18.622.0/ 49 51.6 21 20.677.2 97 100 R2R / - LEAN (R2R) 4 20-22
2554 18 32. / 2. 68 ( 1-2) (R2R2P) 19 R2R ..2553 .. 2554 warfarin
13 R2R 2 R2R 1 3738.1 2 3132.0 3 4 4.1 4 7 7.2 5 1818.6971003. R2R
4 3 (Human Capital) (Structural Capital) (Information Capital)
(Internal process Perspective) / 3.1 15 R2R R2R 255419 33. 3.2
3.2.1 R2R R2R R2R 3.2.2 3.2.3 (R2R) 4 20-22 2554 20 34. / 1. 5 5 .
. . . . . 2. R2R 255421 35. 3. : : , , , , , , , , , , , , , /
(paradygm shift) home health care / (self care/management) 4. , /
(R2R) 4 20-22 2554 22 36. 5. 24 admission Missed injuries : , , ,
.. , , , .. , , .. , , .. , .. .. R2R 255423 37. (R2R) 4 20-22 2554
24 38. 1 R2R 2554 25 39. (R2R) 4 20-22 2554 26 40. 1 R2R 255427 41.
ID28 : , , 2552 34 47 3-6 1 3 1) 1.1) 1.2) 2) 3) 8 1 4 3 1 24 (R2R)
4 20-22 2554 28 42. 1 16 () 2,590 / 59 1) 2) 3) 1) 2) 3) / R2R 2554
29 43. ID116 : 2553 Node (CUP) (CUP) 5 , , , (KM) 36 2553 2553 3
Node 91.13 86.48 78.51 87.35 INHOMESS 2 ticks (R2R) 4 20-22 2554 30
44. . . . R2R 2554 R2R 2554 31 45. ID182 , , , 20 .. 2549 .. 2551
.. 2551 25 .. 2552 2552 2554 3 1 2 3 3 (R2R) 4 20-22 2554 32 46. 1)
2) 1) 2) 3) 1) 2) 3) / R2R 2554 33 47. ID236 : 1) 2) 3) 4) 4 1 2
(A-I-C) 3 4 1) 2) (1) (2) (3) (4) 3) (R2R) 4 20-22 2554 34 48. / /
R2R 255435 49. ID278 , , .. .. 2551 7 282.47 63 2,452.32 42
1,634.88 . .. 1) 2) 3) 4) .. 6 2551- 2554 .. 2551 / - .. 24 . ..
2554 60,000 .. 2552 .. 2554 (R2R) 4 20-22 2554 36 50. . .. 2552 8 2
.. 2553 .. 2554 1 1 1 / .. 1 .. (MOU) R2R 255437 51. ID314 58 38
65.52 20 34.48 .. 1) 2) . 60 1 2 1 . 2552- 2554 . .. . . (R2R) 4
20-22 2554 38 52. 20 14 70 6 .. 2552 3 1) 2) / . . 60 1 R2R 2554 39
53. (R2R) 4 20-22 2554 40 54. 1 R2R 255441 55. ID54 : , , 2552-
2553 50.5 140 mg/dl 12.8 200 mg/dl () HbA1c 2 2553- 2553 200% HbA1c
7.5 20 Wilcoxon signs rank test 0.05 (P0.01) HbA1c (P0.05) 1) 200
mg/dl HbA1c 7.5 (R2R) 4 20-22 2554 42 56. 2) 3) 2 6 / 1 R2R 2554 43
57. ID90 .. (..) 12.56 20.51 .. 2552 .. 2553 .. manual .. 1) .. 2)
HOSxP .. HOSxP .. - .. 2553- .. 2554 .. .. 15 ( 22.72) 1.30 (R2R) 4
20-22 2554 44 58. 0 .. 19 ( 28.78) 45 .. .. .. .. .. .. .. .. / ..
.. HOSxP R2R 255445 59. ID163 (..) .. - 22 2553 9 1) . 3 2) 3 3) 4)
../. 5) 6) 7) 8) 9) 57.60 76.71 65.35 78.26 () (R2R) 4 20-22 2554
46 60. 2 .. 2552 16 .. 2553 1) 2) 3) 4) 6) 7) (../.3S/) / 1) 2) R2R
255447 61. ID173: , , , ! 48 2551- 2554 3 1 2 3 (R2R) 4 20-22 2554
48 62. 1) 2) 3) 4) / R2R 2554 49 63. ID185 , , , 4 ( .. 2550)
50:100,000 .. 6 3,965 557 3 ( .. 2551 1 , .. 2552 2 , .. 2553 4 )
50:100,000 7 500 95 1) 2) 1) 1-6 56 , . 15 5 2) 3) 10 4) 2553 2554
() 1 7 7 500 // (R2R) 4 20-22 2554 50 64. 100 / R2R 2554 51 65.
ID248 10 : , , 100 Plan Do Study Act 100 3 (.) . . .. 2552-2554 82
45 45.4 17.5 66.6 59.7 70.2 . 20 8 3 10 . 128 6 (R2R) 4 20-22 2554
52 66. 2 /. 10 10 10 R2R 2554 53 67. ID354: 2552- 2553 1 3 19 11 30
.. . 32.95 38,634.17 (R2R) 4 20-22 2554 54 68. 1) 2) 3) / 1) 2) R2R
255455 69. (R2R) 4 20-22 2554 56 70. 1 R2R 2554 57 71. ID4 , , , ..
.. Pap smear Speculum .. 1) 2) 3) A4 1 3 1 () 2 () 3 () 2 () .. 555
2 28.80 ( 23.1) 33.70 32.09 26.20 1.88 98.12 Inflammation 47.91
Candida spp. 43.8 .. 62.50 0.97 (R2R) 4 20-22 2554 58 72. 1) . . ()
2 2) 2 () .. .. .. 1) (.) 2) 1) 2554 .. 5 (44 ) 23.1 (204 ) 2) 3) /
. R2R 2554 59 73. ID12 , , 7 2 2551 79 1,726,246 14.6 .. 2549 ..
2538 20 3 4,482 7 . 65 3 2 3 - 2553 . (R2R) 4 20-22 2554 60 74. ()
() () () / R2R 2554 61 75. ID17 , , , 25 140/90 mmHg 200 mg/dl 130
mg/dl 180 mg/dl 105 2 2 1 25 2-20 65 140/90 mmHg 140/90 mmHg 66.66
25 41 180 mg/dl 150 mg/dl 77.77 23 (R2R) 4 20-22 2554 62 76. 3 . 3
6 9 1 1) 2) 3) 1) 2) 1) 2) / 2 R2R 255463 77. ID39 . , , 3
2550-2554 1,183,801 (18.49 ) 27,052 (15.91 ) 47.86 17.86 9.11 1) 2)
35 34.29 28.57 11.43 91.4 42.86 25.71 97.14 (R2R) 4 20-22 2554 64
78. 1) 2) 3) 4) . / . 97 R2R 255465 79. ID44 . 35-40 2551 2552 ..
4.6 50 10 .. 2553 .. 2554 . . . 6 1,313 1) 2) . 3) . 3 4) 50 . 5)
6) . 2 7) . 8) . 1 9) 1 2553-25 2554 . . 4.6 56.7 7.78 41.3 96 .
100 83.3 . 91 .4 (R2R) 4 20-22 2554 66 80. . .. . / .. . . 50 57
R2R 255467 81. ID71/ , 11 11,234 1,242 11.07 1 1,018 ( 82) 2 187 (
15) 3 37 ( 3) 30 - 2554 1 . 3 2 3 () 30 6 628 1) 96.67 2) 2 100 3)
100 (R2R) 4 20-22 2554 68 82. 1) 2) 3) 1) 2) 3) 4) / R2R R2R 2554
69 83. ID79 , , , 2552 2553 15 12 1) 2) (R2R) 4 20-22 2554 70 84. /
15 12 R2R 255471 85. ID98 skin traction Introchanteric 90% neck of
femur 95% skin traction skin traction 1-2 skin traction skin
traction skin traction skin traction 1-2 skin traction skin
traction 2 : 2552- 2554 5-7 2552- 2554 12 skin traction 5 6 DM, HT,
Gout, IHD (R2R) 4 20-22 2554 72 86. 59-92 1 skin traction skin
traction 1 : 12 11 skin traction 100 1) skin traction 2) 3) 4) 1)
skin traction 2) skin traction 1 3) 1) 2) /1) 2) skintraction Skin
traction R2R 2554 73 87. ID130 7 - .. 2553 7 2 WTSD (HAS) 2 5 1 2 5
1-31 2554 80 2 23 5 57 41-50 28.8 ( 17 76 46.5 ) 56 70 100 53.8 ()
17.5 1-2 33.8 500 81.2 ( 5 1,500 282.2 ) 87.5 (R2R) 4 20-22 2554 74
88. 12.5 HAS (Healthy: H) (Accessibility: A) (Safety: S) 61.3 16.
9. 5. 15. 5 100 / 1) (HAS) 2) R2R 2554 75 89. ID135 , .. 2551 147 3
.. 2550 6 50 2552 1 (1-3 /) / (R2R) 4 20-22 2554 76 90. 2-3 0-6 85
60 50 35 0-5 141 1 76 60 100 48.9 / 3 R2R 2554 77 91. ID158 : 16
Thyroid Stimulating Hormone (TSH) 6 1) 2) . . . 16 3) 4) 5) Urine
Iodine TSH 6) 6 91 (R2R) 4 20-22 2554 78 92. 90 93 6 98 , 100 100
16 .. 2554 / R2R 255479 93. ID186 Metabolic Syndrome , , , 1 300 8
1.5 5 5 . (Metabolic Syndrome) 34.78 15.85 ( 1,432 ) .. 2550 2551
15.6 21.8 Metabolic Syndrome . - . 47 45 3 12 12 t-test (R2R) 4
20-22 2554 80 94. P0.001 P0.001 . / 35 2 12 R2R 255481 95. ID188 ,
Children Friendly Hospital -18 350,000 15,000 13 2554 7 2554 3 1)
2) 3) / 1) 175 2) 30 3) 150 1 175 175 96.57 3.43 (R2R) 4 20-22 2554
82 96. 2 3 3 / / / 175 30 150 R2R 255483 97. ID190 , , 5 ..
2548-2552 27.3, 26.3, 24.6, 29.3 27.9 5 .. 2550 2552 31 Thyroid
Stimulating Hormone (TSH) 11.25 11 35.48 1 2552-30 2553 1,272 0.05
. . 100% (R2R) 4 20-22 2554 84 98. .. 2551-2552 20.88 20.69 .. 2553
97.05 (P0.001) 1) 2) .. / 20% 97% R2R 255485 99. ID193: .. 2552 . .
.. 2554 .. 2553 8 533 4-6 1) 2) 3) 8 32 35 220 153 70 12 (FPG
100-125 mg/dl) 38 17-18 2553 6 3. 2. (R2R) 4 20-22 2554 86 100. 1)
(FPG 100-125 mg/dl) 38 FPG100mg/dl 30 (78.95) FPG 100-125 mg/dl 8 (
21.06) 2) (HbA1c) 43 HbA1c7 16 (37.21), HbA1c 7.1-9 13 (30.23)
HbA1c9 14 ( 32.56) HbA1c7 22 ( 51.16), HbA1c 7.1-9 13 ( 30.23)
HbA1c9 8 ( 18.60) 3) 4) (Best Practice) 2 2553 5) .. 2553 ( ) / R2R
255487 101. ID202 slim up .. 2542 35 9 3 3-5 5 30 .. 2553 118 71 79
63 2553 .. 2554 25 3 6 15 1 (BMI) 18 72 BMI 5 20 BMI 2 8 3 (R2R) 4
20-22 2554 88 102. 30 / BMI BMI R2R 255489 103. ID219 , , , R2R ..
2552 1) 2) 3) 4) 3 1) 2) 25 3) 3 3 3 1) 2) 3) 1,781 26.9 4.8 44.7
69.5 1 57.1 1) 2) 3) 4) 5) 6) 7) 8) (R2R) 4 20-22 2554 90 104. / 3
8 R2R 2554 91 105. ID237 .. CUP - , CUP 2553 1 16 .. .. 7 .. 5-6
CUP - .. 1) .. 2) .. 4 CUP - 2553 3 1 7 .. .. 1 .. 2553 2552 ..
2552 UC 77,073 18,454 23.94 2553 UC 76,217 25,579 33.56 2552 60
2553 105 75.00 (R2R) 4 20-22 2554 92 106. 2554 / 6 .. . 1) 2) 3) /
.. .. 1 .. .. 3 R2R 255493 107. ID244 .. 2551-2553 18 31 45 15 7 30
20 1) 2) 3) / 4 1) // 2) 3) 60 4) 2 1) (R2R) 4 20-22 2554 94 108.
2) 75 / 4 / 4 200 Hula Hoop 4 . / . 60 R2R 255495 109. ID280 , , 40
- .. 2553 ( 51) 48.33 5 3 (R2R) 4 20-22 2554 96 110. ( 98) 5 . / 48
R2R 2554 97 111. ID292 , , 35 9 .. 2552 5,167 1.86 5.19 12.08 6.99
. 9 11 1 2553- 2554 1) 2) 3) Spirometer 4) 5) 6) . 7) 11 10 (
99.91) 1 ( 09.09) 30-39 1 50-59 5 60-69 3 70-79 2 5 ( 45.45) 50-59
4 ( 36.36) 60-69 1 ( 9.09) 5 ( 45.45) 70-79 2 ( 18.18) 30-39 1 (
9.09) 50-59 1 ( 9.09) 1 ( 09.09) Normal Spirometry 9 ( 81.81) Mild
Restriction 1 ( 9.09) Moderate Restriction 1 ( 9.09) 7 ( 63.63) 3 (
27.27) 1 ( 9.09) 5 2 ( (R2R) 4 20-22 2554 98 112. 18.18) 2 ( 18.18)
1 ( 09.09) 1) 2) 3) 4) 40 5) / R2R 255499 113. ID327: , , , .. 2544
.. 2549-2550 1) 2) 3 .. 2551 .. 2552 20,000 400 2 5 4 5 4 (R2R) 4
20-22 2554100 114. 5 5 / R2R 2554 101 115. ID328 , , 6 .. 2549 30
.. 2548 14.5 6 27 -- .. 2549-2552 1 4-6 4-12 2 4 2, 4 2, 4 6 3 1) 6
27 64 100 2) 10 -1 86 Hot Line 24 6 37 .. 2550 (R2R) 4 20-22
2554102 116. .. 2551 42 46.55 .. 2552 3) Hot Line 24 10 12 6 / 6 6
5 R2R 2554 103 117. ID333 , , , 40 3 2552- 2552 5 160/110 mmHg 48
40 3 / (R2R) 4 20-22 2554104 118. 1) 2) 3) / 3 R2R 2554 105 119.
ID340 , . . 1 . . 2552 2553 12 2 2553 2554 . . 1 .. . 1 . .. . . .
1 4,500 1 1,500 45 1,500 7,500 7,500 20 4,660 5 23,300 . . (R2R) 4
20-22 2554106 120. 1) . 2) .. . 3) 4) 5) .. 4 3 . / ... 2554 .. ..
.. .. . 2-3 R2R 2554 107 121. ID363 , , .. . . 26 2553 2554 7 1) 2)
3) 4) 5) 6) 7) Peak Flow Meter 18 (R2R) 4 20-22 2554108 122. (
60-80%) 6 ( 33.3) 18 () / ? R2R 2554 109 123. (R2R) 4 20-22 2554110
124. 2 R2R 2554111 125. (R2R) 4 20-22 2554112 126. 2 R2R 2554 113
127. ID6 , , 2551-2553 0.64, 0.55 0.40 1,000 12,000 / 2 4 2 1,000
Braden Score 16 2 15 4 15 2553 2554 .05 15 2-4=2 1,000 ( 0.34 1,000
4 : 2-4 (R2R) 4 20-22 2554114 128. 1) 2) 1) 2) 3) / R2R 2554115
129. ID43 3 .. 2549-2551 253 12 // ( 36 217 ) () 2,024 1 2551 31
2554 160 160 100 88.52 75 96.88 ( 95 //) 2 (R2R) 4 20-22 2554116
130. / R2R 2554117 131. ID48 .. R2R 4 1 2552 31 2553 SPSS 0.05
Microalbuminuria Cardiovascular Risk Score 14.3 89.3 (R2R) 4 20-22
2554118 132. 1) 2) 3) 4) 5) R2R R2R R2R NKF-K/DOQI R2R / R2R 2554
119 133. ID112 , , , .. 2552 3 - 35 2 3 180 4 1) 2) 3) 4) 2553 2553
1) 2) 3) 4) 3 33.62 .05 3 97.73 3 90.60 3 36.55 (R2R) 4 20-22
2554120 134. / R2R 2554 121 135. ID159 Three in one , , , 1 2552- 1
2553 59 Three in one 1-3 30 1 -31 2553 (mean=4.40, SD=0.61)
(mean=4.57, SD=0.51) 3 100 Three in one Three in one Three in one
(R2R) 4 20-22 2554122 136. 1) 2) 3) 3) 4) 5) Three in one / Three
in one R2R 2554 123 137. ID201 Burkholderia pseudomallei 48 4.4 74
40-60 50-65 ceftazidime 14 150 Ceftazidime Ceftazidime Burkholderia
pseudomallei 1 31 2553 27 (HosXP) (R2R) 4 20-22 2554124 138. 27 13
48.2 14 51.8 25.9 61 46.6 (SD=17.9) 18.5 14.8 1 5 51.8 6 10 25.9 19
24,519 17 13,964 5,001 10,000 66.7 22 81.5 100 25 92.6 1-6 .. 1) 2)
3) Ceftazidime .. Formal Informal .. / CUP - R2R 2554 125 139.
ID206 CONDOM : Permanent catheter condom , , (Permanent catheter:
PC) 3-6 subclavian vein PC 9 53 18 100 2 2-3 253,000 condom / 3 PC
condom 9 7 PC fixumo 550 /10 1 . 0.55 PC fixumo 45 ./ 24.75 PC
fixumo /25 ./ 13.75 condom fixumo 10 . 5.5 PC 79.3 PC 60 fixumo
69.65 (27.50 )=13,860 1 PC 1 PC 3 1) PC condom 1 2) PC condom 2
condom 2 3) condom fixumo 96.0 (R2R) 4 20-22 2554126 140. : : 60 ..
2552,2553 PC condom condom Empowerment condom condom condom /
condom permanentcatheter Condom R2R 2554 127 141. ID233 , , 1) 2)
3) serum creatinine 1.5 mg/dL 1 2552 31 2552 STATA version 8
Creatinine clearance (CrCl) 207 CrCl 24.5 ml/min 29.9 53.6 13.5 102
167 ( 49.3) 98 ( 58.7) Antibiotic ( 24.3) Histamine blocker ( 21.6)
Anti-gout ( 20.3) Thiazide diuretic ( 30.1) Sulfonylurea ( 29.0)
Biguanide ( 22.6) 4.67 1,995.78 (R2R) 4 20-22 2554128 142. 1) Serum
creatinine 2) 3) 4) 5) .. 2553 1,500 / Lean Statistical Process
Control Chart R2R 2554129 143. (R2R) 4 20-22 2554130 144. 2 R2R
2554131 145. ID5 1 2549-2552 , , 3 .. 2549, .. 2550 .. 2551 2.77 /,
2.74 / 2.59 / 10, 26.50 21.50 1 1 1 1 2 1 3 3 clinpro 37%
Phosphoric acid gel 45 .. 2549 470 236 234 .. 2550 503 279 224 ..
2551 436 211 225 .. 2552 331 165 166 4 4 (R2R) 4 20-22 2554132 146.
.. 2549, 2550, 2551 .. 2552 72.66, 79.17, 93.19 84.77 20.79, 12.22,
3.86 10.66 6.53, 5.07, 1.00 3.09 1.35, 3.54, 1.93 1.45 12 .. 2552 (
.. 2548) .. 2553 ( .. 2549) 1.79 / 1.3 / 38.8 48.02 1) 2) / R2R R2R
2554133 147. ID15 , 234 .. 2551 529 .. 2552 1-15 1 .. 2552-30 ..
2553 reliever controller (inhaled
corticosteroids/corticosteroids+LABAs) 3 1) 30 ..2553 2) 11 ..2553
3) 28 .. 2553 1 1-3 3 6 paired t-test SPSS P0.05 4 1) 2) 3) 4) 112
80 71.43 (R2R) 4 20-22 2554134 148. 57 ( 71.25) 46 ( 57.5) 3 43 (
53.8) 20 ( 25) ( skin prick test) 50 2 / 60 56.25 69.09 1 3 6 67.5
93.75 P 0.05 / R2R 2554 135 149. ID36 Modified Early Warning Signs
Score , Modified Early Warning Signs Score (MEWSS) ICU - .. 2552 ..
2553 MEWSS4 MEWS 0.05 MEWSS .. 2552 MEWSS4 1,987 .. 2553 2,219
13.23 15.06 68 58.24-60.12 2552 2553 1.14 1.71 (P=0.134) 3.31 1.71
(P0.001) ICU 3.92 2.15 (P0.001) (R2R) 4 20-22 2554136 150. 1.86
1.39 (P=0.236) 8.30 8.04 MEWSS MEWSS MEWSS MEWSS MEWSS / Modified
Early Waring Signs R2R R2R 2554137 151. ID42 , , .. 2549 6 1.30 ..
2551 24.5 6 .. 2551-2552 27.27 34.25 2552 78 Lactogenesis 50 1 2553
31 2553 2 1) 3 1.1) 1.2) 1.3) 2) LATCH Score 17-34 LATCH 30 92 72
98 72 88 86 98 (R2R) 4 20-22 2554138 152. 16 94 LATCH Score
(P=0.001) 6 6 WHO 6 30 50 .. 2555 / Exclusive BreastFeeding 6 Phase
III lactogenesis ( ) R2R 2554139 153. ID57 , , , 3 (2550-2552)
4,213.50 1) 2) 35 - 2553 3 1 2 ICWN 3 3 Chi-square test Hygienic
hand washing //Set IV injection parts 70% alcohol Syringe injection
parts Sterile gauze P0.05 (R2R) 4 20-22 2554140 154. alcohol 1) 2)
3) / R2R 2554 141 155. ID332 , , .. 2542-2551 85 .. 2549 .. 2542
89.87 53.22 .. 2550 70 .. 2542-2550 82.28 .. 2550-2552 , 2552 3,097
- 2552 3 2 2 1) 10.26 2) 9.99 .. 2552 2.62 .. 2552 1.10 0.90 3 75
16.67 10 1 8.33 (R2R) 4 20-22 2554142 156. 1) 2) 2.1) 2.2) 2.3) 3)
2553 2554 . .. .. (20 ) .. 2553 10 1) , 2) 1) 2) 3) /1) 2) R2R R2R
2554143 157. ID346 5 2551 343 35 /76 10.2 10 2-6 4.7 2 0.58 4 1.16
1) 2) 3) 1 ( 2551- 2552) 210 10 /11 4.7 1 0.47 2 ( 2552- 2553) 225
5 2.2 1 0.44 .. 2551 10.2 4.7 (R2R) 4 20-22 2554144 158. 1 2.2 1 2
/ R2R 2554145 159. ID357 , , (NAPHA) ..2548 CD4 CD4 Viral load case
manager CD4 viral load CD4 2553 30 2554 HIV 2550- 2553 2547 2553
168 2552 HosXP 2552 NAPHA (R2R) 4 20-22 2554146 160. CD4 viral load
CD4 viral load 26 87 CD4 viral load CD4 68 100 1) 2) 3) 4) 5) 2 /
R2R 2554147 161. (R2R) 4 20-22 2554148 162. 3 R2R 2554 149 163.
(R2R) 4 20-22 2554150 164. 3 R2R 2554 151 165. ID108 , , , aspirin,
clopidogreal, ACE-I, b-blocker, statin 30 .. 8 prospective cohort
with historical controlled cohort (Percutaneous Coronary
Intervention: PCI) .. 2551 .. 2553 PCI 6 6 3 1 24 PCI 2 3 6 PCI 160
79 81 ACE-I, b-blocker (100% vs. 72%, P0.001 100% vs. 61.5%,
P0.001) 6 ACE-I b-blocker (100% vs. 84%, P0.001 100% vs. 82%,
P0.001) 130/80 mmHg (64.5% vs. 35%, P0.001) (4.9% vs. 13.9%,
P0.005) (R2R) 4 20-22 2554152 166. 2553 100 1.7 International Forum
onQualitySafety in Healthcare Journal Medicine Association of
Thailand2011; 94 (Suppl. 1) / 6 R2R 2554 153 167. ID110 -131 , , ,
(-131) 30 / ( 100 /) ( 150 /) -131 1) - 131 2) 53 -131 26 () 27 ()
6 11.5 14 59 ( . 29 , . 30 ) 3 1) 2) 3) 10 ( 22, 5 2 . 24, 3 3 .)
96.4 . 93.4 . 1 . 0.32 . 0.39 (P=0.781) (R2R) 4 20-22 2554154 168.
2 22 1 (.) 9.1 2 24 1 (.) 8.3 1 5 -131 2 (R2R) / (-131) / -131 R2R
2554155 169. ID115 Dexamethasone , , Dexamethasone hypersensitivity
reaction Dexamethasone Dexamethasone 9 Dexamethasone 10 93 3 1
Dexamethasone 1 2 Dexamethasone 10 2 3 Dexamethasone 50 10
Dexamethasone Fishers exact Dexamethazone 10 70.97 2 Dexamethazone
50 (Onset) 1 44.35 (SD=43.94) 2 71.29 (SD=58.85) (Duration) 1 47.42
(SD=55.07) 2 49.73 (SD=43.89) 1 48.39 22.58 2 58.84 16.13 3 3
(P0.001) (R2R) 4 20-22 2554156 170. Dexamethasone 50 10 /
Dexamethasone R2R 2554 157 171. ID118 , , , 0.26-3.2 88.79
0.19-4.20 4.2 19 (vocal nodules) (vocal polyps) (edema) (Maximum
Phonation Time) (Relative Average Perturbation) 10 : 4 10 8-10
10-12 (R2R) 4 20-22 2554158 172. /: R2R 2554159 173. ID125 -131 , ,
(-131) 50 .. 2499 387 Randomized controlled trial 150 -131 74 4 1
150 / 100 / 10.2 8 25 40 1 -131 (R2R) 4 20-22 2554160 174. 6 45 (
64.3) 59 ( 78.7) 21 ( 30) 36 ( 48) (259.6 305.5 P=0.008) (10,942.79
13,422.78 P=0.050) R2R (R2R) / R2R R2R 2554 161 175. ID164 6 , , ,
200 - 6 ( 1 ) - .. 2552 .. 2553 - 10 (LATCH Score) 1 1, 2, 4 6 20
10 (R2R) 4 20-22 2554162 176. 5 1 1, 2, 4 6 2 (Exclusive
breastfeeding) 6 15-18 2 2 16 3-4 / Obtulator R2R 2554 163 177.
ID170 1 5 24 CBC, hemoculture, electrolytes CBC, electrolytes,
hemoculture 24 , Cross-sectional study . 2552 (6 ) 73 2553 (7 ) 77
: t-test, chi-square, post test likelihood ratio of CBC CBC
bacterial infection 30 50 post-test likelihood ratio=2.8
hemoculture, electrolytes calcium, magnesium, albumin, hemoculture
38 (R2R) 4 20-22 2554164 178. / evidence guideline R2R 2554165 179.
ID197 24 Missed injuries , , , (Primary survey) (Secondary survey)
(Definitive care) Primary Secondary survey Initial resuscitation 24
(Tertiary survey) 24 . (missed injuries) Trauma audit 2546- 2547
107 Missed injuries 11 10.28 9 81.82 2551 2447 Missed injuries 43
1.76 Missed injuries 3 1 2 3 2552 2553 1 1) 2) 3) 2552 2,292 50
Missed injuries 15 0.65 Fracture extremity (8 ) Abdominal injury
(2) Fracture facial bone (2 ) Fracture L1 (1) Eye injury (1 )
Vascular injury (1 ) (R2R) 4 20-22 2554166 180. 2.12 70 24 2553
3365 23 Missed injuries 8 0.24 extremity (4 ) Fracture rib (2 )
Fracture T12(1 ) Fracture clavicle (1 ) 3.89 65.22 24 Blunt injury
Sedative / R2R 2554 167 181. ID218 , , , 2548-2549 Skin and soft
tissue 11.2 9.88 1 2549- 2550 3 2549 2550 451 10.16 3.77 .05 3,742
2,697 (R2R) 4 20-22 2554168 182. 1) 2) - 3) / R2R 2554169 183.
ID223 Knee Exercise , , , (closed fracture distal femur) Rage of
motion Flexion90 .. 2552 96 ( CPM) 295,000 Knee Exercise (KE) 34 1
2552 -31 2553 2 17 24 1 - Quadriceps Exercise - 2 Fowlers position
3-7 KE KE 1 15 2 KE 15 15 3-7 KE 50 50 1 7 , KE KE t-test 2 KE
24.65 (15-46 ) KE 25.29 (16-46 ) KE 90 17 4.41 KE (R2R) 4 20-22
2554170 184. 9 6.37 2 (P0.005) KE 9.52 KE 5.29 KE 64.7 KE 83.5 KE
Knee Exercise KE 1,000 CPM 295,000 , KE KE / . R2R 2554 171 185.
ID269 , , , ( IC) 60 ICU ICU Ventilator-Associated-Pneumonia (VAP)
IC CQI VAP .. 2539-2542 VAP 50% VAP VAP (Zero VAP) VAP Zero Goal
ICU percentile 25 non-ICU percentile 50 benchmark VAP .. 2548-2550
1) Ventilator Care Working Group 2 ( 2551 2553) 2) 3) 4) Maharat
VAP bundle (1) 30-45 (2) oral care 0.12% Chlorhexidine (3)
continuous drip (4) keep cuff pressure 20-30 cm H2O (5) 72 5) 2 (1)
VAP Daily Goal Sheet (2) Weaning Protocol (6) cuff pressure 30-45
7) ICU 8) VAP Champion Day 2553 1) VAP UHOSNET 2) VAP champion 3)
VAP UHOSNET (8/1000 ventilator days) .. 2553 6.09/1000 ventilator
days .. 2554 (-) 5.69/1000 ventilator days (R2R) 4 20-22 2554172
186. VAP champion 7 Zero VAP ( VAP ) 8 1 VAP 216 / 59,192,640 /
evidence-based ICU non-ICU ICU non-ICU Daily Goal cuff pressure 1)
2) 3) 4) VAP Champion / VAP Champion VAP R2R 2554173 187. ID356
Model Reload (Esophageal variceal ligation: EVL) .. 2544 (5,000 /)
EVL EVL Recycle 8 EVL 6 48 EVL Recycle 50 Model 300 / 150 / Reload
EVL Reload 100 / ( 8 + 54 /) EVL 20 2550-2553 EVL 262, 247, 230 262
1,185,800, 1,112,300, 1,029,00 1,107,400 .. 2550, 2551, 2552 2550
EVL (R2R) 4 20-22 2554174 188. Model 30 20 / / (5,000 /) recycle
reload 150 / 30 R2R 2554175 189. (R2R) 4 20-22 2554176 190. 3 R2R
2554177 191. ID34 : , , , 85 80 60 40 2551- 2552 159 4 1 6 (NANDA)
(Carpenito) content analysis 5 ( 100) ( 97.3) ( 61.7) ( 60.4) (R2R)
4 20-22 2554178 192. ( 39.6) 5 1) () / () 2) () () () 3) () () ()
4) () / () 5) : /// () NANDA Template / R2R R2R 2554179 193. ID65 ,
, , .. 2552 144 698 20.6 OR/LR N.S 36.5 80 20 25 1 2553-30 2553 594
new born record P0.001 22-25 Incubator 35 / (R2R) 4 20-22 2554180
194. 22-25 Incubator 35 R2R 2554181 195. ID78 , , , 10-100 1 ..
2550 100 1 100:1, 10:1 20:1, 30:1 100:1 randomized block design 4
80 320 4 100:1, 30:1, 20:1 10:1 1 80 (R2R) 4 20-22 2554182 196.
(30:1) median time () 96 20:1 100:1 ( 70 ) (Normal solution) median
survival 48 4 (96 ) 30:1 100:1 / R2R 2554183 197. ID134 , , ,
(Triage) (OPD Card) 41 380 380 8 - 4 1 1 2 1 6 3 6 4 (R2R) 4 20-22
2554184 198. 1) 4 (Resuscitative) (Emergency) (Urgent) (Non-Urgent)
2) () 96.06 66.58 56.44 26.58 21.10 - 3) 4) 84 / R2R 2554 185 199.
ID143 : 5.5 , , , Pap smear Pap smear - Pap smear 6 .. 2547 ..
2547-.. 2551 901 1-11 2852 Pap smear 2552- 2553 , Standard life
table methods, Cox models Atypical squamous cell of undetermined
significance (ASCUS+) 15.4 37 7 (3 ) American Society of Colposcopy
and Cervical Pathology (ASCCP) 1 CD4 count350/.. ASCUS+ CD4 count
(Pap smear) 6 (R2R) 4 20-22 2554 186 200. Pap smear 6 2 CD4
count350/.. - / 42,030 identify HIV Par Smear R2R 2554187 201.
ID230 : , , .. 2545 medigut NG feeding Cut down 2 .. 2545-2553 12
.. 2545 22 35-45 12 0 80 1 200-300 / (R2R) 4 20-22 2554188 202. Cut
Down 2 / medigut NG tube Cutdown ENT 1 .. 2545 80 20 R2R 2554 189
203. ID238 , , , .. 2547 135 111 ( 82.22) 24 13 ( 66.66) 13 2552-
2554 3 1 2 (APN) 3 1) .. 2550 80 2) 5 3 1 20 (
http://www.youtube.com/watch?v=j9btdDRRNmc,
http://www.wishingwellthai.org/) 2 18 3 15 . . . . (R2R) 4 20-22
2554190 204. 4 5 3) / R2R 2554191 205. ID252 2 , , , 60-70 100-120
25-30 / / 2 2 20 2550-19 2551 2 ( ) 95% two-tailed 80% 34 16 40 -
7-9 8, 16 24 SPSS T-test (R2R) 4 20-22 2554192 206. 8 (P.16) 16, 24
(P.01) (P.01) 1) 2) 2 24 / R2R 2 : R2R 2554 193 207. ID313 , , 115
26 3 1) 2) 3) 1) 2) 3) 23.67 1 (R2R) 4 20-22 2554194 208. / R2R R2R
2554195 209. ID347 , , 72 1-3 17 1-5 ( 1.88 ) 2 1-3 ( 1.76 ) 3 1-3
( 1.52 ) 1) 2) 3) 4) 5) 6) 7) 30 (R2R) 4 20-22 2554196 210. 1-2
86.67 88.3 2 1 2 1-2 86.67 R2R 2554 197 211. (R2R) 4 20-22 2554198
212. 3 R2R 2554199 213. ID37 / / : 2553 2553 1) 2) 20 -12 2553 5 1)
2) 3) 4) 5) Rating scale 0-3 1-3 6 Flouxetine 5 4-5 4 Diazepam 2 mg
10 8 1 (R2R) 4 20-22 2554200 214. 9 2,448 8,329 29 - 12 2553 4,965
1,667 Diazepam 2 mg 1,991 Flouxetine 1,240 3 / R2R 2554201 215.
ID93 Ceftriaxone , , Ceftriaxone ceftriaxone ceftriaxone Randomized
cross over clinical trial ceftriaxone 2 2553 67 ( 134 ) A: 20 B:
100 1 Rank sum test Exact probability test 67 ( 134 ) 51.1
(SD=16.8) 18 84 53.7 (SD=10.1) 158.3 . (SD=5.8) 21.4 /2 (SD=3.6)
ceftriaxone 2.4 (SD=0.8) A 2 ( 3) 1 2 ( 3.0) 2 1 ( 1.5) B 3 ( 4.5)
1 3 ( 4.5) (P=0.500) A 8 ( 11.3) B 3 ( 4.5) (P=0.116) (R2R) 4 20-22
2554202 216. (P=0.500) 8 ( 11.3) 3 ( 4.5) (P=0.116) ceftriaxone
ceftriaxone ceftriaxone ceftriaxone / Randomized cross over
clinical trial ceftriaxone 100 20 Inclusion Exclusion criteria R2R
2554 203 217. ID107 , 24-48 15-20 1 30 15 48 48 80 48 48 (R2R) 4
20-22 2554204 218. 30 48 (P.05) (P.05) 1) 48 2) 3) 4) / routine
sample size R2R 2554205 219. ID113 Polyethylene glycol Sodium
phosphate , , . 3 1) 2) sodium phosphate (NaP) 3) Polyethylene
glycol (PEG) 2 3 3 NaP PEG randomized equivalent clinical trial 150
1 2553-30 2553 3 1 Unison 60 , 2 NaP 30 , 3 PEG Milk of Magnesium
60 Grading of bowel preparation 5 Multivariable logistic regression
150 1:1.02 54 3 (P=0.84) (P0.001) NaP 5.49 PEG 2.65 (P0.001, 0.007
) 3 PEG 0.5 (P=0.04) 3 (P=0.09) NaP (P=0.99) PEG 0.48 (P=0.04) NaP
(P=0.64) PEG (P=0.52) 3 NaP 9.48 (P=0.05) PEG (R2R) 4 20-22 2554206
220. 3.74 (P=0.26) : PEG NaP 1) NaP PEG 2) / R2R 2554 207 221.
ID119 Burirams model paracetamal (500 .) 2 diazepam (5 .) 1 80 90,
39.5x44.5 . 60 70 50 70 1) 2) - 2553 30 1) Burirams model 1.1) 1.2)
1.3) - 1.4) 1.5) 1.6) 2) Burirams model 93.3 90.0, 73.3, 70.0,
70.0, 63.3 60.0 (R2R) 4 20-22 2554208 222. / R2R 2554209 223. ID123
50 1 5 1 10 .. 2546 .. 2548 PCU CVA CARE MAP TEAM STROKE CORNER 28
726 .. 2546 320 406 .. 2548 2 .. 2546 8.7 3.4 .. 2548 40.3 .. 2546
33.3 .. 2548 (P0.01) 8.1 6.1 .. 2546 .. 2548 (P0.01) 28 5 1.5 ..
2546 .. 2548 (P0.01) 15,231 11,244 .. 2546 .. 2548 (P0.01) (R2R) 4
20-22 2554210 224. ICD 10 . 3 .. 2550 . (STROKE UNIT) .. 2552 ..
2554 / stroke unit stroke corner R2R 2554211 225. ID127 Gas/Silcone
oil Gas Silicone oil .. 2551 718 Gas Silicone oil 534 Gas Silicone
oil 1-2 16 15 1-2 Gas/Silcone oil Gas Silicone oil - 2551 100 (R2R)
4 20-22 2554212 226. 60 2 96 18.17 1 18.07 2 , 3 , 4 , 5 6 17.63,
17.81, 18.68, 18.94 19.80 Gas Silicone oil Gas Silicone oil
/Gas/Silicone oil R2R 2554213 227. ID131 , , , Cloth Wrap Non-
Cloth Wrap 1 2553 30 2553 300 Cloth wrap 150 Cloth wrap 150 (Cloth
Wrap) Temperature Record 19.3 4.96 Cloth wrap Cloth wrap 1) Body
Wrap: Clothes/ gloves/socks 2) Head Wrap: Hood/Hat 3) Crib Wrap:
Plastic Wrap .. 2553 4.96 (R2R) 4 20-22 2554214 228. / Cloth Wrap
R2R 2554 215 229. ID187 , 90 1-2 3 SLE 50 / 25 3 - 0.90 0.92 t-test
(R2R) 4 20-22 2554216 230. (mean=27.36, SD=3.07) (mean=17.48,
SD=3.64) (P=0.000) (P0.05) (mean=51.20, SD=4.82) (mean=36.20,
SD=4.77) (P=0.000) / R2R R2R 2554217 231. ID189 , , ( 26 3-4 ) 1-3
.. 2553 544 2,544 21.30 2549 2553 Chi-Square test Fishers exact
test 80 45 (56.25%) 35 (43.75%) 7-91 10 21-60 69 86.25 7 8.80 73
91.30 65 81.25 9 13.85 7 10.77 46 70.77 3 4.61 62 95.38 88.71 88.71
59.7 54.8 (P=0.048) (R2R) 4 20-22 2554218 232. R2R 2554219 233.
ID211 Bonding Elective , - 1) Elective 2) 1) Elective - 30 30 2)
Elective 30 2.1) 4 Bonding 2.2) 2.3) 3) - 4) 1 2553-31 2553 5) 5.1)
5.2) 2 Bonding () 2 () 20-39 11 54 2 3.13 6 6 2 1.86 (R2R) 4 20-22
2554220 234. 1) Elective 2) 1) 2) /1) 2) (.) : c/s R2R 2554 221
235. ID212 PJ , , , 90 3 1 2552- 2553 96 2 1 1 34 2 3 62 1 90 6
10.6 2 50 3 90 4.4 8.8 2 85.7 90 1.6 1.8 3 2 35.7 3 (R2R) 4 20-22
2554222 236. 1) 2) 90 3) 1) 2) 3) / R2R R2R : R2R 2554223 237.
ID225 , 10-18 6 6 30 2551- 2552 2 5 2 10 1) 50 2) Foot Function
Index (FFI) 6 Chi square test, Fishers exact test Independent t
test SPSS 13.0 FFI (P0.001) 6 (P=0.02) FFI (P=0.03) 10 80 6 80
(R2R) 4 20-22 2554224 238. 5-10 10 2 / R2R 2554225 239. ID282 , 3
(targeted therapy) fluoropyrimidine irinotecan oxaliplatin
oxaliplatin (neuropathy) 90 / neuropathy oxaliplatin extravasation
oxaliplatin infusion 2 / oxaliplatin oxaliplatin oxaliplatin
infusion 2 2 34 (R2R) 4 20-22 2554226 240. oxaliplatin (P.05) 1) 2)
3) 4) / 26-37 oxaliplatin 5-25 38-48 oxaliplatin 26-37 R2R 2554 227
241. ID291 Modified Lying Position , ( 36.6 .. 2547 43.6 .. 2551)
Modified Lying Position (MLP) Side Lying Position (SLP) 24 32 MLP
SLP 3 4 MLP SLP 1) (mean=1.14, SD=1.357 mean=3.98, SD=2.277) 2)
(mean=1.95, SD=1.568 mean=5.31, SD=2.143) 3) (mean=1.14, SD=1.363
mean=5.26, SD=2.148) (mean=1.08, SD=1.363 mean=1.13, SD=1.431)
(P=0.05) MLP SLP mean=7.93, SD=.716 mean=8.11, SD=.834 (P=0.05) MLP
(R2R) 4 20-22 2554228 242. 1) : 2) : 1) 2) / 32 16 Pain score 0-10
2 R2R 2554229 243. ID312 , , (Percutaneous Coronary angiography) ..
2551 2552 2553 223, 522, 475 4-10 (thrombosis or embolism) sheath
17 2532- 2553 90 88.25 88.25 sheath 2553 (R2R) 4 20-22 2554230 244.
/ R2R 2554231 245. ID337 , , , () - .. 2549-2550 1 3 80 Rooting
reflex Sucking reflex 4 randomized controlled trial 4 2552- 2553 37
naloxone 2,500-4,000 APGAR scores 17 59 2 96 104 stratified
randomized allocation sealed opaque envelope technique 1015 SPSS
Unpaired t-test (R2R) 4 20-22 2554232 246. ( 87.5 74 , P=0.02)
(6.72+11.09 7.26+10.50 P=0.73) ( 83.3 91.3 , P=0.09) Rooting reflex
Sucking reflex 4 (R2R) / - RCT R2R 2554233 247. ID355 , , 2 10 340
(Desferrioxamine) 96 (Serumferritin) () 3 1) 2 2) 3) 12 2 2553 20
1) t-test 2) 10-Point Visual Analog Scale (VAS) 20 2 (Iron
overload) 2 (R2R) 4 20-22 2554234 248. 1 2 / The 12th International
Conference on Thalassaemia and Other Haemoglobinopathies, and The
14thTIF Confarence for Patients and Parent in Turkey R2R (efficacy
: R2R 2554 235 249. (R2R) 4 20-22 2554236 250. 44A 4B R2R 2554 237
251. (R2R) 4 20-22 2554238 252. 4 R2R 2554 239 253. ID18 , 6.56
400-500 . 250 . 250 . 20-30 250 . 1 .. 2550 30 .. 2551 1 .. 2551 30
.. 2553 250 . 20-30 P0.05 Control P-chart 30,195 41,963 1,518 985
5.0 2.3 (OR=2.2, 95%CI=2.0-2.4, P0.001) control chart lower control
limit (OR=1.8, 95%CI=1.6-2.0) (OR=6.4, 95%CI=5.6-7.4) (OR=1.7,
95%CI=1.5-1.9) (OR=7.5, 95%CI=6.4-8.7) (P0.001) Hyperventilation
(R2R) 4 20-22 2554240 254. 400-500 . / ( ) 1 4 R2R 2554241 255.
ID21 , *, WEBIS 1 Gram Cryptococcus - internet (Virtual Microscopy:
VM) 1 100 website internet / web board Bamaras-VM website
www.bamras-eqa.com 1,000 website ( , , , Bamras-VM 1 2551 20 2554
1,698 (3,572 ) 49 (269 ) Bamras-VM (R2R) 4 20-22 2554242 256. /-
R2R 2554243 257. ID31 , , (Gravity) 20-25 7-10 LPG 20 15 15 12 20
12 3 20 20 15 20 12 1) 100 2) 100 3) 100 20 115 1.05 121 7 20 15 5
150 1,825 10 5 60 (LPG) 1.05 111 10 300 3,650 4 20 12 8 240 (R2R) 4
20-22 2554244 258. 2,920 35 17.5 213 1.05 84 37 1,110 13,505 (
2,920 ) 3 Lean 13,505 2553 / R2R 2554245 259. ID33 , , 80 20 1) 2)
3 1 2 3 3) 20 1 16 80 2 4 20 3 100 (R2R) 4 20-22 2554246 260. R2R /
R2R 2554 247 261. ID50 Internet , , , 3 . 3 .. 2552 ./. 5 5 3 2552-
2553 398 192 ( 48.24) 5-7 ( 14 ) 20 25 60 ( 1 ) 60.41 . 3 Internet
2553 2553 Internet UC 15 .. 2553-2554 - 2553 5 276 internet 149 (
53.99) internet 127 ( 46.01) internet 63 ( 49.61) 3 2 (1 -31 2554)
5 280 internet 190 ( (R2R) 4 20-22 2554248 262. 67.85) internet 70
( 32.15) 33 (47.14) internet 1 20-25 14 12 2 1 Internet Care-map,
CPG (Cancer Referral center) Internet Scan . 31) 2) IT 3) /
Intervention 5 R2R 2554 249 263. ID121 MONITOR ALARM WATER PUMP
MONITOR ALARM WATER PUMP (NURSE CALL) 2551- 2553 MONITOR ALARM
WATER PUMP 28 1) MONITOR ALARM WATER PUMP 2) 3) MONITOR ALARM WATER
PUMP 100 4 4) (R2R) 4 20-22 2554250 264. 1) ( ) 2) R2R 2554251 265.
ID140 Facebook: Adult . , , 17.64 3.92 (Facebook) 3 4 51 15 2553-
2554 Adult . (Blueprint) E-mail group 2-3 10-15 3 3 92.16 90
(mean=4.37) (mean=4.18) (mean=4.12) (mean=4.39) (R2R) 4 20-22
2554252 266. (mean=4.29) (mean=4.28) 3 1) 2) / Intervention
facebook R2R 2554253 267. ID157 , , , 72 9 .. 2548 10 4 5 (5 mSv/h)
( ) 8 1 .. 2548 .. 2549 9.5 1 .. 2552 1 (9.5 ) ( ) 1) 2) 15 .. 2549
5 (2549-2553) 15 .. 2549 37.5 25.7, 15.9, 12.7, 12.0 .. 2550-2553
15 15 .. 2549 32.0 28.6, 22.5, 20.5, 12.5 .. 2550-2553 (R2R) 4
20-22 2554254 268. / R2R R2R 2554255 269. ID183 : eStock online
Delivery , , , 2553 . dead stock 37,247,001.20 2553 (- 2553) 9
38,497,388.21 14 1) 2) 3) Lean Concept 3 (4 2553-6 2553) 3 1) 2) 3)
1 2 eStock 3 3 (4 2553-6 2553) 1) : 16,961,132.70 ( 2553)
10,572,153.49 ( 2553) 6,388,979.21 37.67 2) 14 6.94 50.43 3) 76.25
83.71 81.20 82.24 (R2R) 4 20-22 2554256 270. (Innovation Logistic)
1) Chain Collaborate 2) Lean System Alliance 3) 5Rs Delivery: Right
Time, Right Place, Right Item, Right Quantity Right Quality / ()
R2R 2554 257 271. ID229 () , , 8 (IP: Internet Protocol) (Internet
Telephony) VoIP (Voice over IP) IP Telephone - . 8 . 8 .. 2553
6,917,200 8-9 3-4 36 . 8 8 IP Telephony 25 . 8 .. 2553 14,279.96
6,153.92 57 97,512.48 (R2R) 4 20-22 2554258 272. VoIP, 12 64 71.35
/ Intervention 80 2 R2R 2554 259 273. ID271 STEMI , , , 1 STEMI 70
7 STEMI 4 1) 2) STEMI EKG STEMI 3) 4) STEMI 60 .. 2552 170 92 16.7
10.1 100 90 61.5. 72.1 14.9 11.7 44 .. 2552 48 .. 2553 88 ward
STEMI EKG EKG e-mail MMS 15 STEMI STEMI 1-2 clopidogrel STEMI (R2R)
4 20-22 2554260 274. ACS ER ACS EMS Member club STEMI CPR STEMI
STEMI STEMI Mobile ICU STEMI Pitfall in STEMI STEMI STEMI / (.)
Intervention Node R2R 2554261 275. ID310- LEAN - - - Lean - - - 2
1) - - 30 3 5 3 - 14 - 2,506.7 1 26 3,013.4 2 14 1 14 - 3 1 - 3
9.00 16.00 . 1 3 Lean (R2R) 4 20-22 2554262 276. 70% Noncritical 1
OK (OK ) - 31 769 Lean PDCA- - / R2R 2554263 277. ID316 5 10 . ..
2552-2553 STEMI (ST-Elevation Myocardial Infarction) 1-2 1) (, , ,
) 2) . 10 5 ( ) 11 .. 2552 INR . 10 3 12 () (Target INR) 700 9
1,000 1 () 4 1 INR (R2R) 4 20-22 2554264 278. . 10 5 1) 2) . /
Intervention Model Development R2R 2554265 279. ID348 TACE ,
(Transcatheter hepatic arterial chemoembolization: TACE) ( ) 1-3
TACE 2 5 ( .. 2552-2553) TACE 2 () 1 4 (2-18 ) 1 1 TACE 2 1 1 1) 3
(2-5 ) (13 1 ) 2) 3) (3-7 70) 4) 15 28 ( 1 ) TACE (Descriptive
studies) (retrospective) TACE 1 2552 28 2554 1 (R2R) 4 20-22
2554266 280. 5-152 14-30 96 30 2-18 1-2 6,000 15 28 3 3 / R2R
2554267 281. ID366 Decha Program , , , 6 360 24.00-08.00 . Decha
Program Decha Program 1) Decha Program 2) 3) 3 (12 2551-12 2552) 4)
5) 2552- 2553 ( 1) 2553- 2554 ( 2) 6) (16.00-24.00 .) 7) 8) 2 48.61
80 10 / 3 / 5.33 (R2R) 4 20-22 2554268 282. / logbook R2R 2554269
283. (R2R) 4 20-22 2554270 284. 4 R2R 2554 271 285. ID8 , , , 100 2
1 2 1 2 2 2 . 2553- .. 2554 1) 2) 3) (R2R) 4 20-22 2554272 286. 4)
5) 85% / R2R 2554273 287. ID82 , , , 8 .. 2553 (On top payment) 1)
2) 12 /18 28 28 14 .. 2553 ( ) 569 2 1,138 2552 2554 1) Excel file
2.48 .. 2553 0.12 .. 2554 2) 2553 58.54 82.10 .. 2553 3) 3.1) : . 8
10, 11 (NP-Udon Model) .. 2552-2553 907 69.55 (GIS) 100 3.2) :
(R2R) 4 20-22 2554274 288. 5,000 / 3.3) : Stakeholder 3.4): ..
2553-2554 73.87 91.15 (GIS) .. 2553-2554 1.60 3.08 (0.88)3.5) : (
82.7) 1) 8 : 2) 10, 11: (.) 3) : 4) : 5) : R2R 2554 275 289. ID88
High kVp Technique , ALARA ICRP High kVp Technique kVp mAs 7 2553-
2554 11 kVp true - 55 15% ( kVp 15% mAs ) 15% ( mAs Contrast ) kVp
mAs 15% mAs (R2R) 4 20-22 2554276 290. 15% mAs Contrast High kVp
Technique 27.27 High kVp Technique 15% 0.22 0.16 27.27 1) 2) 3) 4)
R2R High kVp Technique kVp kVp mA 11 / High kVp Technique 55 1 R2R
2554277 291. ID152 , , .. 2553 6-7 ( 35 ) 1 () 2 10 (R2R) 4 20-22
2554278 292. 1) 2) / R2R 2554 279 293. ID349 elective (elective
surgery) crossmatch to transfusion ratio (C/T ratio) 2.5 97.56
4,567 84.96 C/T ratio 6.65 2 Group matching (G/M) type and
screening (T/S) 2 1) 2) 2552 2552 (G/M T/S) ASA class 1, 2 ( 78.4)
TUR-P 38 ( 20) Cholecystectomy 11.1 Esophagectomy 2 ( 1.1)
hematocrit 30 Hematocrit (IQR) 37 ( 32.75-40) 115 (70-170) 100
(50-300) . (R2R) 4 20-22 2554280 294. / R2R 2554281 295. (R2R) 4
20-22 2554282 296. 4 R2R 2554 283 297. ID45 , 7 9,904.44 7,012.16
2,876.43 15.85 1) 2) 3) (R2R) 4 20-22 2554284 298. / R2R 2554285
299. ID64 Step .. 2548-2552 120 728 Step 1) 2) 3) 1 30 ..2553 35 10
5 4 3 2 1 16 19 45-60 85.7 3.62 3.57 24.2 16.3 7.9 1 (R2R) 4 20-22
2554286 300. , , / R2R 2554 287 301. ID75 (FM-PRM/1-01) , , ,
8.00-12.00 . 107 (FM-PRM/1-01) 23.78 23.78 2554 23.78 85 15 5.24 95
(R2R) 4 20-22 2554288 302. lean / R2R 2554289 303. ID85 , , , 300
.. 2552 .. 2552 56 1 14 1) 2) 3) 4) 3 1 3 2 A B 1 07.00 .-16.00 . 3
3 5 1) Immediate lift-threatening 2) Emergency 10 3) Urgency 30 4)
Semi- urgency 1 5) Non-urgency 2 (R2R) 4 20-22 2554290 304. 95.65 (
0) 90.21 ( 0) 5 1) Immediate lift-threatening 100 ( 98.42) 2)
Emergency 10 100 ( 93.83) 3) Urgency 30 100 ( 60.36)4) Semi-urgency
1 100 ( 78.03) 5) Non-urgency 2 100 ( 88.74) 0 97.72 ( 48.58) 0 /
// ( ) R2R 2554 291 305. ID126 , .. 2542 2552 2 3 59 110 .. 2547 1)
2) 3) 50 1 2 3 4 60 2.60 (R2R) 4 20-22 2554292 306. 4.52 4 / R2R
R2R 2554293 307. ID129 : , , , (6 ) 1) 6 (8-10 ) 2) 3X 300 1 2552
1) 2) 3) 1) ( 5 3 ) 2) 45 ( 1 2-3 ) 1 3) 4) ( 4.63) (R2R) 4 20-22
2554294 308. 5) 6) 1) 8 2) / R2R 2554 295 309. ID133 Water Jet Pump
, , , 1 Syringe 50 . .. 2553 .. 2554 / (R2R) 4 20-22 2554296 310.
R2R 2554 297 311. ID154 , , , .. 2546 (Thailand Quality Award) 943
0.03 MJ. Marquardt 2 8 5 50 Rating Scale 5 =5 =4 =3 =2 =1 - 2551 (
3.50) 3.74 3.36 CoP 3 (3.82) (3.46) (3.53) (3.43) (R2R) 4 20-22
2554298 312. (3.52) 5 1) 2) CoP 3) 4) 5) 6) 1) 2 2) / 1) 2) 3) /
R2R R2R 2554 299 313. ID165 , . Taro Yamane 603 720 1 2554 31 2554
832 28.88 66.59 33.41 35.92 50.00 1-3 35.22 30 52.64 88.10 90.50
(R2R) 4 20-22 2554300 314. 70.95 70.87 28 .. 2551 1 107 .. 2551 409
374 .. 2553 / ( ) R2R 2554 301 315. ID167 Active Supervision Model:
1 / / Professional Sharing 5 3 1 (2549): 82.79 38.40 2 (2550-2551):
16 84.91 28.16 3 (2552-2553): Active Supervision Model Balanced
Scorecard 2 3 On The Job Monitoring 1) Balanced Scorecard 81.28
30.63 2) 75.19 96.47 3) 87.19 19.65 4) (R2R) 4 20-22 2554302 316.
83.67 27.35 5) 79.14 44.57 91.46% Sensitive KPI Balanced Scorecard
/ R2R R2R 2554303 317. ID191 .. 2551-2553 130 714 13 .. 2543-2547 2
TSH .. 2548-2550 27.3, 26.3, 24.6 2 .. 2551 TSH 11.25 mm/L 32.34 20
.. 1 2551 30 2553 212 . (R2R) 4 20-22 2554304 318. TSH 11.25 mm/L
32.34 .. 2551 24.40 21.78 .. 2552 2553 (P0.001) 1) 2) 3 3) 4) ..
... . / R2R 2554 305 319. ID249 50 14 8 600 One Stop Service 14 52
2552- 2553 1 1) 2) 3) 4) 2 1) Online 2) 3) 4) 3 14 7 20 600 50
(P0.01) One Stop Service (R2R) 4 20-22 2554306 320. One Stop
Service 4 1) 2) 3) 4) / CQI CQI R2R R2R 2554 307 321. ID250 , ..
2550 30 (Retinopathy of Prematurity: ROP) .. 2550-2552 162, 171,
181 ROP 48.15, 46.78 46.40 ( 47.11) ( 3-4) 10 3 1 3 2 20 2 2 3
2551- 2553 () 201 (294 ) 100 ROP 242 ( 82.31) ROP ( 1-2) 39 (
13.27) 47.04 ROP ( 3-4) 13 ( 4.42) 45.21 2553 2 (R2R) 4 20-22
2554308 322. ROP ROP ( 3 ) ROP 1, 2 / ROP 3 / ROP R2R 2554309 323.
ID296 3 .. 2551, 2552 2553 167, 113 250 1 3 PCT .. 30 5 13 6 5 4 2
() 1 1 5 ( 16.66) 265-385 644-764 2 2 22 ( 73.33) 359-479 727-817 3
3 3 ( 10) 852-887 150 mg/dl 150 mg/dl .. .. 1 / () (R2R) 4 20-22
2554310 324. .. 150 mg/dl R2R / R2R 3 1 / ( ) .. .. R2R 2554311
325. ID298 CUP-- , / / / 2 1 7 / 2 2 7 .. - 22 .. - 22 .. .. 2553
1) / 2 1 7 2) / 2 2 7, 10 14 / (Steam Autoclave) (Lot) 3 Negative /
4 7, 10, 14 15 / 26-30 (R2R) 4 20-22 2554312 326. 76-78 31-35 -
81-84 1) 2 1 7 2) 2 2 14 1) 2 2 14 2 1 7 2) .. 22 .. 3) / 0 4)
Re-sterile 1) 22 .. 2) 22 .. 3) 1) 2) /1) 3 5 2) Sterile - CUP R2R
2554 313 327. ID300 : 200 1,000 100-150 2 40 .. 2552 3 11 Microsoft
Access 2003 Microsoft Windows XP 11 .. 2552 40 5 (R2R) 4 20-22
2554314 328. / 1 () R2R 2554 315 329. ID336 2009 (H1N1) 2009 (H1N1)
.. 2552-2553 4 1) 2) 3 3) 741 2552 2553 (e-mail) 4) 6 (R2R) 4 20-22
2554316 330. 741 704 ( 95.0) 8 ( 1.1) 29 ( 3.9) 189 ( 25.6) 29 (
3.9) 523 ( 70.5) 48 5 (SRRT; Surveillance and Rapid Response Team)
/ H1N1 R2R R2R 2554 317 331. ID339 Lean Laboratory , , 90
07.00-12.00 . Lean Laboratory 3 1) 2) Lean Management 3) 1) 2) Lean
thinking IT LIS 3) Request Lab Turn around timed 91.25 98 0.011
0.003 75 95 74 92.9 77.2 89.72 Reject specimen 0.0025 0.0008 (R2R)
4 20-22 2554318 332. 1) 2) 3) 4) Lean Council / Lean Concept LA LA
R2R 2554319 333. ID343 , , , 60 (Medication management system) 2551
2550 2551 28,487.63 21,012.04 7,475.59 2551 2552 82,513.18
51,836.07 1.6:1 / (R2R) 4 20-22 2554320 334. / / R2R 2554321 335.
ID371 ADR , , , (Adverse drug reaction: ADR) 3 .. 2551-2552
Bactrim, Ibuprofen Amoxycillin Phenytoin Steven Johnson Syndrome
(SJS) 1 SJS Phenytoin 1) 2) SJS 2552- 2554 3 1 2551- 2552 PCU 3 SJS
1 2 Internet SJS Co-trimoxazole 3 ADR 6 ADR PCU - 56.10 80 HCIS,
Family folder Sticker 2552- 2554 PCU 15 2,125 ADR Type I 221 ADR
Type II 1,904 14 93.33 (R2R) 4 20-22 2554322 336. PCU 33 8
Anaphylaxis 2 11 73.33 1 411 1) 2) PCU 1) PCU 2) PCU 3) / / PCU R2R
2554323 337. (R2R) 4 20-22 2554324
